drugset
drugset / Trial / NCT04701164

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

NCT04701164 ↗

Phase 3 Completed 242 enrolled Annexon, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is intended to evaluate the efficacy and safety of ANX005 administered by intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome (GBS). The total duration of study participation is approximately 6 months.

Timeline

Start
2020-12-17
Primary completion
2024-04-20
Completion
2024-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX005 Protein / enzyme biologic — Intravenous

Indications

Guillain-Barre syndrome